Headquartered in Westworks, White City Place, London, UK. Investors include Netherton Investments (a fund investing on behalf of Mike Platt) and Dompé farmaceutici S.P.A. For more information, visit ...
Engitix plans to use the funds for preclinical development across its pipeline in solid tumors and fibrosis, and to expand ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
Medical Device Network on MSN
StimLabs launches Allacor P for acute and chronic wound care
StimLabs has announced the launch of Allacor P, a human umbilical cord device designed for acute and chronic wound management ...
“This review explores our current understanding of how ECM geometry influences the behaviors of both immune cells and tumor cells, which in turn impacts treatment efficacy and cancer evolutionary ...
PITTSBURGH--(BUSINESS WIRE)--ECM Therapeutics, a clinical stage regenerative medicine company pioneering the development of Extracellular Matrix-based therapeutics for the treatment of unmet medical ...
Scientists have developed a synthetic extracellular matrix (ECM) that can support the growth of a mini endometrium in a dish for at least two weeks. The endometrium -- the mucosal lining of the uterus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback